Royalty Pharma (RPRX) Other Operating Expenses (2019 - 2026)

Royalty Pharma has reported Other Operating Expenses for 8 years, with the latest figure at -$131.8 million in Q1 2026.

• Quarterly Other Operating Expenses fell 3.63% year-over-year to -$131.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$160.9 million (down 840.84% YoY) and the FY2025 annual result came in at -$206.8 million, down 128.23% from the prior year.
• Other Operating Expenses retreated to -$131.8 million in Q1 2026 per RPRX's latest filing, from $18.8 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $924.7 million in Q4 2022 and troughed at -$227.6 million in Q3 2024.
• A 5-year average of $148.9 million and a median of $118.8 million in 2023 frame the typical range for Other Operating Expenses.
• The widest YoY moves for Other Operating Expenses: up 391.23% in 2024, down 182.13% in 2024.
• Over 5 years, Other Operating Expenses stood at $924.7 million in 2022, then plunged by 108.27% to -$76.5 million in 2023, then soared by 314.39% to $164.0 million in 2024, then plunged by 88.52% to $18.8 million in 2025, then slumped by 799.47% to -$131.8 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered -$131.8 million, $18.8 million, and $12.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.